Which Weight Loss Treatment Matches Your Needs?
Mounjaro vs Wegovy for Weight Loss: Understanding the Complete Dose Journey
When comparing Mounjaro vs Wegovy for weight loss, the most crucial factor is understanding that both require identical dose escalation schedules over 16+ weeks. Wegovy (semaglutide) works as a GLP-1 receptor agonist, whilst Mounjaro (tirzepatide) functions as a dual GIP and GLP-1 receptor agonist, potentially offering different mechanisms of appetite control. Both treatments start at 0.25mg for weeks 1-4, progress to 0.5mg for weeks 5-8, then 1mg for weeks 9-12, followed by 1.7mg for weeks 13-16, before reaching the maintenance dose of 2.4mg from week 17 onwards.
At EverydayMeds, we recognise that your Mounjaro vs Wegovy for weight loss decision shouldn't be complicated by supply issues or pharmacy changes mid-treatment. Our comprehensive stock of every dose means you can complete your entire escalation journey with one trusted provider. Whether your prescriber recommends the single GLP-1 approach of Wegovy or the dual-action mechanism of Mounjaro, we maintain consistent supply chains and cold-storage protocols to ensure your treatment never faces interruption.
Complete Pricing Comparison: Mounjaro vs Wegovy for Weight Loss Investment
Understanding the financial commitment when comparing Mounjaro vs Wegovy for weight loss requires transparency about the complete dose progression costs. For Wegovy, our pricing structure reflects the increasing complexity of higher doses: 0.25mg costs £79.99, 0.5mg at £94.99, 1mg at £99.99, 1.7mg at £139.99, and the maintenance 2.4mg dose at £209.99 per pen. New customers apply discount code FIRST40 at checkout, whilst returning customers use DOSE25 to access these competitive rates. Mounjaro pricing follows a similar escalation pattern, though specific costs vary based on current supply agreements with manufacturers.
Our bundle options for both Mounjaro vs Wegovy for weight loss treatments provide convenience rather than just cost savings, ensuring seamless progression through dose levels. The Intro Trio bundle (0.25mg, 0.5mg, and 1mg) costs £299.99 for Wegovy, covering your first 12 weeks of treatment in one order. For patients reaching maintenance levels, our Ultimate Stability Trio provides three months of 2.4mg supply for £649.99, eliminating monthly reordering concerns. These bundles apply to both treatments, allowing direct comparison when making your Mounjaro vs Wegovy for weight loss decision.
Clinical Evidence: How Mounjaro vs Wegovy for Weight Loss Compare in Studies
The clinical evidence base for Mounjaro vs Wegovy for weight loss comes from separate trial programmes with different study designs and patient populations. Wegovy's efficacy was demonstrated in the STEP trial series, with STEP 1 showing patients achieved approximately 15% average weight loss at 68 weeks when combined with reduced-calorie diet and increased physical activity (Wilding et al., NEJM, 2021). Mounjaro's SURMOUNT trials evaluated tirzepatide's dual-action mechanism, though direct head-to-head comparisons between these trials aren't scientifically valid due to different methodologies and endpoints.
Both treatments in the Mounjaro vs Wegovy for weight loss comparison require prescription-only medicine status and clinical assessment to determine suitability. The mechanisms differ significantly - Wegovy targets GLP-1 receptors exclusively, whilst Mounjaro's dual GIP and GLP-1 receptor activity may influence glucose-dependent insulin secretion and gastric emptying through additional pathways. Your prescriber will evaluate which mechanism aligns better with your individual health profile and weight management goals.
How Wegovy Works: GLP-1 Mechanism for Weight Management
Wegovy functions as a GLP-1 receptor agonist, mimicking the natural incretin hormone glucagon-like peptide-1 that your body produces after eating. This mechanism reduces appetite by acting on brain centres that control hunger and satiety, helping patients feel fuller after smaller meals and potentially reducing food cravings between meals. The once-weekly injection via FlexTouch pen delivers consistent semaglutide levels, supporting appetite regulation throughout the week when combined with lifestyle modifications. Unlike rapid-acting appetite suppressants, Wegovy's GLP-1 action works gradually to reset eating patterns rather than providing immediate hunger blocking effects. Clinical trials demonstrate this mechanism may help patients achieve sustained weight loss when used alongside a reduced-calorie diet and increased physical activity, though individual responses vary significantly.
Streamlined Ordering Process: From Assessment to Delivery
Our ordering process for both Mounjaro vs Wegovy for weight loss options begins with a comprehensive 3-minute online clinical assessment covering your medical history, current medications, and weight management goals. Following submission, our GPhC-registered prescribers (#9012878) review your assessment within 3 working days (or 24 hours with express service), determining which treatment suits your individual circumstances best. Once approved, our pharmacy team prepares your order using pharmaceutical-grade cold-chain storage, ensuring optimal potency from our facility to your door. Next-day delivery maintains the temperature-controlled environment essential for both semaglutide and tirzepatide stability. Our clinical team remains available throughout your treatment journey to address questions about dose progression, side effect management, or transitioning between dose levels as your treatment advances.
Storage and Practical Considerations: Mounjaro vs Wegovy for Weight Loss
Storage requirements represent a practical advantage when considering Mounjaro vs Wegovy for weight loss, particularly for patients who travel frequently or have limited refrigerator space. Wegovy can remain at room temperature (below 30°C) for up to 6 weeks once removed from refrigerator storage, compared to Mounjaro's 21-day room temperature limit, providing greater flexibility for holidays or business travel. Both treatments require refrigeration at 2-8°C before first use and utilize pre-filled pen devices for once-weekly injection. The FlexTouch pen system for Wegovy includes dose confirmation windows and safety features, whilst Mounjaro employs similar user-friendly injection technology. Dose escalation cannot be skipped for either treatment - the gradual increase from 0.25mg to 2.4mg over 16 weeks helps minimize gastrointestinal side effects whilst optimizing therapeutic benefit for sustainable weight management.
Long-term Treatment Planning: Your Complete Dose Progression Journey
Planning your long-term success with either option in the Mounjaro vs Wegovy for weight loss comparison requires understanding that weight management extends far beyond initial dose escalation. Most patients remain on the maintenance 2.4mg dose indefinitely, as clinical evidence shows weight regain occurs when treatment discontinues. Our pharmacy model supports this reality by maintaining consistent stock levels of maintenance doses and offering quarterly supply bundles to reduce reordering frequency.
The choice between Mounjaro vs Wegovy for weight loss becomes particularly important at maintenance levels, where the different receptor mechanisms may influence long-term tolerability and effectiveness. Some patients find the dual GIP/GLP-1 action of Mounjaro provides different satiety signals compared to Wegovy's GLP-1-only approach, though individual responses vary considerably. Our clinical team tracks patient progress through regular follow-up assessments, helping optimize dosing schedules and addressing any concerns that emerge during extended treatment periods.
Expert Support: Making Your Treatment Decision with Confidence
Both Wegovy and Mounjaro are available from EverydayMeds - your prescriber can help determine which treatment aligns best with your health profile and weight management objectives. Our clinical assessment process evaluates factors including existing medical conditions, concurrent medications, previous weight loss attempts, and lifestyle considerations that may influence treatment selection. Following approval, patients receive detailed injection training materials, dose progression calendars, and direct access to our clinical team for ongoing support throughout their weight management journey. New customers can start their assessment today using discount code FIRST40, whilst existing patients benefit from DOSE25 savings on subsequent orders, ensuring cost-effective access to either treatment option. Begin your clinical assessment now to discover which prescription-only medicine offers the most suitable approach for your individual circumstances and long-term weight management goals.
Reviewed by the EverydayMeds Clinical Team · GPhC #9012878 · Last updated February 2026
